Table 1 MR results of causal effects between endocrine diseases and lymphatic diseases risk.

From: Causal association between endocrine diseases and lymphoid malignancies explored through two-sample Mendelian randomization analysis

Outcome

Exposure

Methods

N. SNPs

OR (95% CI)

P

DLBCL

T2D

IVW

114

1.01 (0.89–1.15)

0.91

  

MR Egger

114

1.03 (0.75–1.4)

0.87

  

Weighted median

114

0.97 (0.76–1.25)

0.81

  

Weighted mode

114

0.98 (0.74–1.3)

0.88

 

Obesity

IVW

8

1.08 (0.85–1.38)

0.53

  

MR Egger

8

1.16 (0.56–2.41)

0.7

  

Weighted median

8

1.07 (0.78–1.48)

0.67

  

Weighted mode

8

1.06 (0.74–1.52)

0.77

 

dHypo

IVW

6

0.91 (0.76–1.07)

0.25

  

MR Egger

6

0.81 (0.62–1.07)

0.21

  

Weighted median

6

0.87 (0.74–1.03)

0.1

  

Weighted mode

6

0.87 (0.73–1.03)

0.16

 

HPL

IVW

15

0.97 (0.86–1.08)

0.57

  

MR Egger

15

1.04 (0.79–1.37)

0.77

  

Weighted median

15

0.92 (0.79–1.06)

0.24

  

Weighted mode

15

0.9 (0.71–1.13)

0.39

 

HTH

IVW

10

1.01 (0.83–1.23)

0.93

  

MR Egger

10

1.83 (1.07–3.13)

0.06

  

Weighted median

10

1.11 (0.89–1.38)

0.37

  

Weighted mode

10

1.16 (0.88–1.52)

0.31

LL

T2D

IVW

113

1.0001 (0.9998–1.0004)

0.64

  

MR Egger

113

1.0007 (0.9999–1.0014)

0.08

  

Weighted median

113

1 (0.9994–1.0006)

0.98

  

Weighted mode

113

1.0001 (0.9995–1.0007)

0.79

 

Obesity

IVW

7

0.9999 (0.9993–1.0005)

0.82

  

MR Egger

7

0.9995 (0.9975–1.0015)

0.62

  

Weighted median

7

0.9999 (0.9991–1.0006)

0.69

  

Weighted mode

7

0.9998 (0.999–1.0007)

0.71

 

dHypo

IVW

7

1.0004 (1-1.0007)

0.03

  

MR Egger

7

1.0008 (1.0003–1.0012)

0.03

  

Weighted median

7

1.0004 (1.0001–1.0008)

0.01

  

Weighted mode

7

1.0005 (1-1.0009)

0.08

 

HPL

IVW

15

0.9999 (0.9997–1.0002)

0.6

  

MR Egger

15

0.9999 (0.9994–1.0004)

0.77

  

Weighted median

15

0.9999 (0.9996–1.0002)

0.5

  

Weighted mode

15

0.9999 (0.9995–1.0002)

0.43

 

HTH

IVW

10

1.0002 (0.9998–1.0005)

0.38

  

MR Egger

10

1.0009 (0.9996–1.0022)

0.23

  

Weighted median

10

1.0001 (0.9996–1.0006)

0.7

  

Weighted mode

10

1 (0.9992–1.0007)

0.92

FL

T2D

IVW

115

1.01 (0.82–1.24)

0.92

  

MR Egger

115

1.23 (0.77–1.97)

0.38

  

Weighted median

115

1.5 (1.09–2.06)

0.01

  

Weighted mode

115

1.49 (0.96–2.31)

0.08

 

Obesity

IVW

7

0.8 (0.53–1.21)

0.29

  

MR Egger

7

0.41 (0.1–1.61)

0.26

  

Weighted median

7

0.73 (0.43–1.24)

0.24

  

Weighted mode

7

0.71 (0.38–1.31)

0.31

 

dHypo

IVW

6

1.13 (0.88–1.44)

0.34

  

MR Egger

6

0.81 (0.56–1.18)

0.33

  

Weighted median

6

1.03 (0.8–1.33)

0.81

  

Weighted mode

6

1 (0.77–1.3)

0.99

 

HPL

IVW

14

1.1 (0.95–1.27)

0.22

  

MR Egger

14

1.09 (0.78–1.52)

0.63

  

Weighted median

14

1 (0.81–1.23)

0.99

  

Weighted mode

14

0.95 (0.72–1.27)

0.75

 

HTH

IVW

11

0.95 (0.72–1.25)

0.7

  

MR Egger

11

0.83 (0.43–1.61)

0.59

  

Weighted median

11

0.92 (0.69–1.23)

0.56

  

Weighted mode

11

0.91 (0.67–1.25)

0.58

NHL

T2D

IVW

115

1.01 (0.92–1.11)

0.82

  

MR Egger

115

0.99 (0.8–1.22)

0.91

  

Weighted median

115

0.99 (0.85–1.16)

0.93

  

Weighted mode

115

0.96 (0.82–1.14)

0.67

 

Obesity

IVW

7

0.98 (0.8–1.2)

0.87

  

MR Egger

7

0.68 (0.34–1.34)

0.31

  

Weighted median

7

0.9 (0.72–1.13)

0.37

  

Weighted mode

7

0.89 (0.71–1.11)

0.33

 

dHypo

IVW

7

0.91 (0.82–1.02)

0.12

  

MR Egger

7

0.92 (0.75–1.14)

0.49

  

Weighted median

7

0.92 (0.84–1.01)

0.07

  

Weighted mode

7

0.93 (0.84–1.03)

0.2

 

HPL

IVW

15

1.06 (1-1.13)

0.06

  

MR Egger

15

0.97 (0.84–1.12)

0.7

  

Weighted median

15

1.03 (0.95–1.12)

0.48

  

Weighted mode

15

1.01 (0.92–1.11)

0.77

 

HTH

IVW

11

1.07 (0.81–1.4)

0.64

  

MR Egger

11

2.29 (0.99–5.3)

0.09

  

Weighted median

11

0.97 (0.82–1.14)

0.71

  

Weighted mode

11

1 (0.8–1.24)

0.97

Lymph node tumor

T2D

IVW

115

0.92 (0.79–1.07)

0.27

  

MR Egger

115

0.89 (0.63–1.24)

0.49

  

Weighted median

115

0.89 (0.68–1.15)

0.36

  

Weighted mode

115

0.92 (0.71–1.17)

0.49

 

Obesity

IVW

7

1.02 (0.75–1.39)

0.89

  

MR Egger

7

1.27 (0.43–3.78)

0.69

  

Weighted median

7

1.02 (0.72–1.46)

0.91

  

Weighted mode

7

1.04 (0.7–1.55)

0.84

 

dHypo

IVW

6

0.95 (0.82–1.09)

0.44

  

MR Egger

6

0.98 (0.77–1.26)

0.9

  

Weighted median

6

0.95 (0.8–1.11)

0.5

  

Weighted mode

6

0.95 (0.81–1.1)

0.51

 

HPL

IVW

14

1.04 (0.95–1.15)

0.4

  

MR Egger

14

1.07 (0.86–1.33)

0.56

  

Weighted median

14

1.08 (0.94–1.24)

0.3

  

Weighted mode

14

1.09 (0.9–1.32)

0.39

 

HTH

IVW

12

0.99 (0.87–1.13)

0.91

  

MR Egger

12

1.09 (0.8–1.5)

0.59

  

Weighted median

12

1.05 (0.88–1.25)

0.59

  

Weighted mode

12

1.05 (0.85–1.29)

0.66

  1. MR, mendelian randomization; N. SNPs, number of SNPs used in MR; IVW, inverse variance weighted; CI, confidence interval; OR, odds ratio; DLBCL, Diffuse Large B-Cell Lymphoma; LL, Lymphocytic Leukemia; FL, Follicular Lymphoma; NHL, Non-Hodgkin’s Lymphoma; T2D, type 2 diabetes; dHypo, diabetic hypoglycemia; HPL, hyperlipidemia; HTH, hyperthyroidism.
Back to article page